DDInter1943 DDInter172
In 1922, vitamin E was demonstrated to be an essential nutrient. Vitamin E is a term used to describe 8 different fat soluble tocopherols and tocotrienols, alpha-tocopherol being the most biologically active. Vitamin E acts as an antioxidant, protecting cell membranes from oxidative damage. The antioxidant effects are currently being researched for use in the treatment of diseases causing bone loss, cardiovascular diseases, diabetes mellitus and associated comorbidities, eye diseases, inflammatory diseases (including skin conditions), lipid disorders, neurological diseases, and radiation damage. Though this research is so far inconclusive, vitamin E remains a popular supplement and is generally considered safe by the FDA[FDA Label].
Belatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it is a homodimer of two homologous polypeptide chains of 357 amino acids each. It is produced through recombinant DNA technology in mammalian CHO cells. The drug has activity as a selective co-stimulation modulator with inhibitory activity on T lymphocytes. It is approved for the treatment of rheumatoid arthritis. Belatacept selectively blocks the process of T-cell activation. It was developed by Bristol-Myers-Squibb. Belatacept is only 2 amino acids different from abatacept (Orencia). FDA approved on June 15, 2011.
Vitamin E {u} (Compound) resembles {v} (Compound) Phylloquinone
Vitamin E {u} (Compound) binds {v} (Gene) NR1I2
Vitamin E {u} (Compound) upregulates {v} (Gene) CDK6
Vitamin E {u} (Compound) downregulates {v} (Gene) PTPRO
Vitamin E {u} may cause a minor interaction that can limit clinical effects when taken with {v} Mogamulizumab
Vitamin E {u} may cause a minor interaction that can limit clinical effects when taken with {v} Infliximab
Vitamin E {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mechlorethamine
Vitamin E {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eptifibatide
Vitamin E (Compound) resembles Phylloquinone (Compound)
Vitamin E (Compound) binds NR1I2 (Gene)
Vitamin E (Compound) upregulates CDK6 (Gene)
Vitamin E (Compound) downregulates PTPRO (Gene)
Vitamin E may cause a minor interaction that can limit clinical effects when taken with Mogamulizumab
Vitamin E may cause a minor interaction that can limit clinical effects when taken with Infliximab
Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Mechlorethamine
Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Eptifibatide